Verdict: Side-by-side breakdown using the Bull Rankings model. PAHC scored 70.7, ZTS scored 55.5 — PAHC leads.
Compare another set
PAHC
Phibro Animal Health Corporation
Drug Manufacturers - Specialty & Generic · Quality-Growth
70.7
$38.30 · $1.6B
fundamentals as of
Score gap
15.2
PAHC leads
ZTS
Zoetis Inc.
Drug Manufacturers - Specialty & Generic · Quality-Growth
55.5
$74.81 · $30.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestZTS12.3x
Fastest growthPAHC+17.1%
Strongest balance sheetPAHC2.06
Highest qualityZTS89 / 100
Largest discount to fair valueZTS-25%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
PAHC
stronger →← stronger
ZTS
61
Qualityreturns · margins · balance sheet
89
81
Growthrevenue & earnings expansion
35
72
Valuevaluation vs sector peers
55
PAHC is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
PAHC
ZTS
$10mC-
FCF
$2.3bB
+17.1%B+
Rev
+1.5%C
2.06D
D/E
2.94D
15.8xA-
P/E
12.3xA
1.68C+
PEG
6.80D
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
PAHC
ZTS
773% above
Price vs fair valuelower is cheaper
25% below
>60%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~-4%/yr
-90%
1-yr DCF upside
+37%
-89%
5-yr DCF upside
+32%
-86%
10-yr DCF upside
+27%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Drug Manufacturers - Specialty & Generic · market cap $1.6b. Down 36% from 52-week high of $60.08 — deep drawdown territory. Revenue growing +17%, comfortably above the S&P median. 4 sell-side analysts rate this a Hold with a mean 1-yr target of $44.00 (implying +15% upside).
Moat
ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.06 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Drug Manufacturers - Specialty & Generic · market cap $30.9b. Down 50% from 52-week high of $148.30 — deep drawdown territory. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $96.00 (implying +28% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 83% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.94 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 50% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where PAHC and ZTS diverge
On the headline score the gap is 15.2 points in favor of PAHC. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
GrowthPAHC 80.6 · ZTS 34.9PAHC +45.7
QualityPAHC 61.2 · ZTS 89.1ZTS +27.9
ValuePAHC 71.7 · ZTS 55.0PAHC +16.7
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is PAHC or ZTS the better stock?
PAHC scores higher: PAHC 70.7, ZTS 55.5 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do PAHC and ZTS differ most?
The widest gap is growth, where PAHC leads by 46 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.
How are PAHC and ZTS scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.